Literature DB >> 21778490

"Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown.

Peter A Newman1, Carmen Logie, Llana James, Tamicka Charles, John Maxwell, Khaled Salam, Michael Woodford.   

Abstract

OBJECTIVES: We investigated how persons from key populations at higher risk of HIV exposure interpreted the process and outcomes of the Step Study HIV-1 vaccine trial, which was terminated early, and implications for willingness to participate in and community support for HIV vaccine research.
METHODS: We used qualitative methods and a community-based approach in 9 focus groups (n = 72) among ethnically and sexually diverse populations and 6 semistructured key informant interviews in Ontario, Canada, in 2007 to 2008.
RESULTS: Participants construed social meaning from complex clinical and biomedical phenomena. Social representations and mental models emerged in fears of vaccine-induced infection, conceptualizations of unfair recruitment practices and increased risk behaviors among trial participants, and questioning of informed consent. Narratives of altruism and the common good demonstrated support for future trials.
CONCLUSIONS: Public discourse on HIV vaccine trials is a productive means of interpreting complex clinical trial processes and outcomes in the context of existing beliefs and experiences regarding HIV vaccines, medical research, and historical disenfranchisement. Strategic engagement with social representations and mental models may promote meaningful community involvement in biomedical HIV prevention research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778490      PMCID: PMC3154228          DOI: 10.2105/AJPH.2011.300208

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  24 in total

1.  Trust, emotion, sex, politics, and science: surveying the risk-assessment battlefield.

Authors:  P Slovic
Journal:  Risk Anal       Date:  1999-08       Impact factor: 4.000

2.  Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Mark B Feinberg; Robert C Gallo; Beatrice Hahn; James A Hoxie; Eric Hunter; Bette Korber; Alan Landay; Michael M Lederman; Judy Lieberman; Joseph M McCune; John P Moore; Neal Nathanson; Louis Picker; Douglas Richman; Charles Rinaldo; Mario Stevenson; David I Watkins; Steven M Wolinsky; Jerome A Zack
Journal:  Science       Date:  2004-01-16       Impact factor: 47.728

3.  Support for the RV144 HIV vaccine trial.

Authors:  Robert Belshe; Genoveffa Franchini; Marc P Girard; Frances Gotch; Pontiano Kaleebu; Marta L Marthas; Michael B McChesney; Rose McCullough; Fred Mhalu; Dominique Salmon-Ceron; Rafick-Pierre Sekaly; Koen van Rompay; Bernard Verrier; Britta Wahren; Mercedes Weissenbacher
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

4.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

Review 5.  Barriers to participating in an HIV vaccine trial: a systematic review.

Authors:  Edward Mills; Curtis Cooper; Gordon Guyatt; Amy Gilchrist; Beth Rachlis; Chris Sulway; Kumanan Wilson
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

6.  Towards a science of community engagement.

Authors:  Peter A Newman
Journal:  Lancet       Date:  2006-01-28       Impact factor: 79.321

7.  HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.

Authors:  Peter A Newman; Naihua Duan; Kathleen J Roberts; Danielle Seiden; Ellen T Rudy; Dallas Swendeman; Svetlana Popova
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

Review 8.  Review of community-based research: assessing partnership approaches to improve public health.

Authors:  B A Israel; A J Schulz; E A Parker; A B Becker
Journal:  Annu Rev Public Health       Date:  1998       Impact factor: 21.981

Review 9.  Risk perception and communication.

Authors:  B Fischhoff; A Bostrom; M J Quadrel
Journal:  Annu Rev Public Health       Date:  1993       Impact factor: 21.981

10.  The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?

Authors:  Jerome A Singh; Edward J Mills
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

View more
  16 in total

1.  Public health messages about perinatal marijuana use in an evolving policy context.

Authors:  Marian Jarlenski; Jennifer Zank; Jill Tarr; Judy C Chang
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

2.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

3.  Acceptability of Cell and Gene Therapy for Curing HIV Infection Among People Living with HIV in the Northwestern United States: A Qualitative Study.

Authors:  Karine Dubé; Jane Simoni; Michael Louella; Laurie Sylla; Zahra H Mohamed; Hursch Patel; Stuart Luter; Ann C Collier
Journal:  AIDS Res Hum Retroviruses       Date:  2019-05-21       Impact factor: 2.205

4.  Legal and ethical values in the resolution of research-related disputes: how can IRBS respond to participant complaints?

Authors:  Kristen Underhill
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

5.  If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities: A Qualitative Focus Group Study.

Authors:  Laurie Sylla; David Evans; Jeff Taylor; Adam Gilbertson; David Palm; Judith D Auerbach; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01       Impact factor: 2.205

Review 6.  Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.

Authors:  Ying-Ru Lo; Carissa Chu; Jintanat Ananworanich; Jean-Louis Excler; Joseph D Tucker
Journal:  AIDS Patient Care STDS       Date:  2015-05-18       Impact factor: 5.078

7.  Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.

Authors:  Peter A Newman; Clara Rubincam; Catherine Slack; Zaynab Essack; Venkatesan Chakrapani; Deng-Min Chuang; Suchon Tepjan; Murali Shunmugam; Surachet Roungprakhon; Carmen Logie; Jennifer Koen; Graham Lindegger
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

8.  "If It's Not Working, Why Would They Be Testing It?": mental models of HIV vaccine trials and preventive misconception among men who have sex with men in India.

Authors:  Venkatesan Chakrapani; Peter A Newman; Neeti Singhal; Ruban Nelson; Murali Shunmugam
Journal:  BMC Public Health       Date:  2013-08-07       Impact factor: 3.295

9.  Crowdsourcing and community engagement: a qualitative analysis of the 2BeatHIV contest.

Authors:  Allison Mathews; Samantha Farley; Lisa Hightow-Weidman; Kate Muessig; Stuart Rennie; Joseph D Tucker
Journal:  J Virus Erad       Date:  2018-01-01

10.  Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling.

Authors:  Elizabeth E Tolley; Kate Morrow Guthrie; Seth Zissette; Joseph L Fava; Katherine Gill; Cheryl E Louw; Philip Kotze; Krishnaveni Reddy; Kathleen MacQueen
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.